MK-8776 (SCH 900776)

For research use only.

Catalog No.S2735

50 publications

MK-8776 (SCH 900776) Chemical Structure

CAS No. 891494-63-6

MK-8776 (SCH 900776) is a selective Chk1 inhibitor with IC50 of 3 nM in a cell-free assay. It shows 500-fold selectivity against Chk2. Phase 2.

Selleck's MK-8776 (SCH 900776) has been cited by 50 publications

Purity & Quality Control

Choose Selective Chk Inhibitors

Biological Activity

Description MK-8776 (SCH 900776) is a selective Chk1 inhibitor with IC50 of 3 nM in a cell-free assay. It shows 500-fold selectivity against Chk2. Phase 2.
Targets
Chk1 [1]
(Cell-free assay)
CDK2 [1]
(Cell-free assay)
3 nM 0.16 μM
In vitro

SCH 900776 is a less potent inhibitor of Chk2 and CDK2 with IC50 of 1.5 μM and 0.16 μM, respectively. SCH 900776 shows no significant inhibition of cytochrome P450 human liver microsomal isoforms 1A2, 2C9, 2C19, 2D6, and 3A4. SCH 900776 induces a dose-dependent loss of DNA replication capability 24 hours after hydroxyurea exposure. SCH 900776 enhances the γ-H2AX response of hydroxyurea, 5-fluoruracil, and cytarabine. In combination with an antimetabolite, SCH 900776 induces accumulation of γ-H2AX within 2 hours, indicative of replication fork collapse and double stranded DNA breaks. Additionally, SCH 900776 suppresses accumulation of the Chk1 pS296 autophosphorylation in a dose-dependent manner. Exposure of proliferating WS1 cells to SCH 900776 is associated with rapid, dose-dependent accumulation of Chk1 pS345, indicating that cycling populations of normal cells induce Chk1 pS345 following exposure to SCH 900776 as part of a futile cycle, perhaps driven by AT-family kinases and DNA-PK.[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
U251 M1TjVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fGdVIxOC9{MECwJI5O NFHtdWYzPCCq MV;k[YNz\WG|ZYOgeIhmKEmFNUCgc4YhT2WvY3n0ZYJqdmV? NEjURpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO1PVUzPid-MkSzOVk2OjZ:L3G+
HCT115 NHvMU3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVeyNFAwOjByMDDuUS=> MXqyOEBp NVfO[Y5T\GWlcnXhd4V{KHSqZTDJR|UxKG:oIFflcYNqfGGkaX7l MmjmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|NUm1NlYoRjJ2M{W5OVI3RC:jPh?=
SW620 NXjwT|BET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvlZ5gzODBxMkCwNEBvVQ>? NFzC[VEzPCCq NG\Eb41l\WO{ZXHz[ZMhfGinIFnDOVAhd2ZiR3XtZ4l1[WKrbnW= MnnyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|NUm1NlYoRjJ2M{W5OVI3RC:jPh?=
IGROV-1 M2D5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlP0NlAxNzJyMECgcm0> M4XPUFI1KGh? NUPrWoNx\GWlcnXhd4V{KHSqZTDJR|UxKG:oIFflcYNqfGGkaX7l NV3oSI5bRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOVk2OjZpPkK0N|U6PTJ4PD;hQi=>
HCT116 M1:5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2T5SlIxOC9{MECwJI5O MWKyOEBp NIjWRpRl\WO{ZXHz[ZMhfGinIFnDOVAhd2ZiR3XtZ4l1[WKrbnW= M{G5WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{W5OVI3Lz5{NEO1PVUzPjxxYU6=
MCF10A M3u1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVKyNFAwOjByMDDuUS=> NIC3T5YzPCCq NGTkSIdl\WO{ZXHz[ZMhfGinIFnDOVAhd2ZiR3XtZ4l1[WKrbnW= NX7HV5JURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOVk2OjZpPkK0N|U6PTJ4PD;hQi=>
MiaPaCa-2 MkDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWWyNFAwOjByMDDuUS=> NF7y[ZQzPCCq MkPm[IVkemWjc3XzJJRp\SCLQ{WwJI9nKEenbXPpeIFjcW6n NWiwTmpWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOVk2OjZpPkK0N|U6PTJ4PD;hQi=>
MDA-MB-231 M1iwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUGyNFAwOjByMDDuUS=> NXW1UZZYOjRiaB?= NUnPN|d2\GWlcnXhd4V{KHSqZTDJR|UxKG:oIFflcYNqfGGkaX7l NH7XN3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO1PVUzPid-MkSzOVk2OjZ:L3G+
HCC2998 M2rnVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2ewOVIxOC9{MECwJI5O NIW5doQzPCCq M2W5XoRm[3KnYYPld{B1cGViSVO1NEBw\iCJZX3jbZRi[mmwZR?= MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN3OUWyOkc,OjR|NUm1NlY9N2F-
U87 NFL4PJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXOyNFAwOjByMDDuUS=> MUmyOEBp Ml;m[IVkemWjc3XzJJRp\SCLQ{WwJI9nKEenbXPpeIFjcW6n MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN3OUWyOkc,OjR|NUm1NlY9N2F-
MDA-MB-435 NIPpfIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYSyNFAwOjByMDDuUS=> MXSyOEBp MofP[IVkemWjc3XzJJRp\SCLQ{WwJI9nKEenbXPpeIFjcW6n NI\TXZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO1PVUzPid-MkSzOVk2OjZ:L3G+
SNB19 NY[xbZp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHm1VoozODBxMkCwNEBvVQ>? MojaNlQhcA>? MnzF[IVkemWjc3XzJJRp\SCLQ{WwJI9nKEenbXPpeIFjcW6n MnyyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|NUm1NlYoRjJ2M{W5OVI3RC:jPh?=
U20S NXHVNXcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUeyNFAwOjByMDDuUS=> MnrWNlQhcA>? MYTk[YNz\WG|ZYOgeIhmKEmFNUCgc4YhT2WvY3n0ZYJqdmV? MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN3OUWyOkc,OjR|NUm1NlY9N2F-
A498 NYi3[|JlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfFRnQzODBxMkCwNEBvVQ>? Mnq3NlQhcA>? NWXLOIRW\GWlcnXhd4V{KHSqZTDJR|UxKG:oIFflcYNqfGGkaX7l MmG4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|NUm1NlYoRjJ2M{W5OVI3RC:jPh?=
TK10 NVrHe3FlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTZNlAxNzJyMECgcm0> NIDDT5ozPCCq Mn\m[IVkemWjc3XzJJRp\SCLQ{WwJI9nKEenbXPpeIFjcW6n MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN3OUWyOkc,OjR|NUm1NlY9N2F-
AsPC-1 M{S3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzte2xTOjByL{KwNFAhdk1? NXLvT|VmOjRiaB?= MmC4[IVkemWjc3XzJJRp\SCLQ{WwJI9nKEenbXPpeIFjcW6n NUPLcXJoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOVk2OjZpPkK0N|U6PTJ4PD;hQi=>
H23 NUDN[m53T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzM[45OPTByIH7N NYHHXo8zOjRiaB?= NHf2RmVFVVOR NYLMRVdE\W6qYX7j[ZMhfGinIHPo[Y1we2Wwc3n0bZpifGmxbjD0c{BRVVh? M1rlT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUGzOVQ6Lz5{NEGxN|U1QTxxYU6=
H1437 M4j0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUe1NFAhdk1? NFXCc2EzPCCq MlGzSG1UVw>? MWPlcohidmOnczD0bIUh[2inbX;z[Y5{cXSrenH0bY9vKHSxIGDNXC=> MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDFzM{W0PUc,OjRzMUO1OFk9N2F-
H1993 NUDQNFFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnwW4Y2ODBibl2= MYqyOEBp M2fBZmROW09? M1LT[4VvcGGwY3XzJJRp\SClaHXtc5NmdnOrdHn6ZZRqd25idH:gVG1Z M3vpTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUGzOVQ6Lz5{NEGxN|U1QTxxYU6=
H1299 MkCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU[1NFAhdk1? NH7BRmgzPCCq MVXEUXNQ NE\LWWtmdmijbnPld{B1cGViY3jlcY9{\W6|aYTpfoF1cW:wIITvJHBOYA>? M1zMOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUGzOVQ6Lz5{NEGxN|U1QTxxYU6=
AsPC-1 NXHyRnlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M333TFExNTFyMECgcm0> NI\hZYIzPC12OHi= MlvE[Y5p[W6lZYOgeIhmKGOqZX3vd4Vve2m2aYrheIlwdiC2bzDn[Y1kcXSjYnnu[S=> MkTtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6MES0NlIoRjJ|OEC0OFIzRC:jPh?=
MiaPaCa-2 M2G3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzVUYwyOC1zMECwJI5O M1vKNlI1NTR6aB?= M{fFPYVvcGGwY3XzJJRp\SClaHXtc5NmdnOrdHn6ZZRqd25idH:g[4Vu[2m2YXLpcoU> MofEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6MES0NlIoRjJ|OEC0OFIzRC:jPh?=
BxPC-3 MljyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3GNVAuOTByMDDuUS=> NETxNYYzPC12OHi= M2nuRoVvcGGwY3XzJJRp\SClaHXtc5NmdnOrdHn6ZZRqd25idH:g[4Vu[2m2YXLpcoU> M3nLeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OEC0OFIzLz5{M{iwOFQzOjxxYU6=
SKOV3 MmfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV[wMlMhyrWP M33xXFgh\A>? M3:wcJNmdnOrdHn6[ZMhfGinIHPlcIwhdGmwZYOgeI8h\2WvY3n0ZYJqdmYEoB?= NFW0fIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W0PFI3QSd-MkO1OFgzPjl:L3G+
OVCAR-8 NYHFZmhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHS4UG8xNjNiwsXN NHTNSWs5KGR? MXLz[Y5{cXSrenXzJJRp\SClZXzsJIxqdmW|IITvJIdmdWOrdHHibY5myqB? NV;zT5lFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OFgzPjlpPkKzOVQ5OjZ7PD;hQi=>
MV-4-11 MlvkRZBweHSxc3nzJGF{e2G7 M2\pNlExOC15MECgcm0> NEHQelM1QCCq MXTpcoR2[2W|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7 NFLYeoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WzOlczOSd-MkO1N|Y4OjF:L3G+
U937 MULBdI9xfG:|aYOgRZN{[Xl? NGroPHMyODBvN{CwJI5O M1jhOVQ5KGh? M{DJTIlv\HWlZYOgZZBweHSxc3nzJIRwe2ViZHXw[Y5l\W62bIm= NInDOnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WzOlczOSd-MkO1N|Y4OjF:L3G+
MOLM-13  Mo\JRZBweHSxc3nzJGF{e2G7 NX;ZUng4OTByLUewNEBvVQ>? M1vheVQ5KGh? NXLwWodjcW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> NE\VR|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WzOlczOSd-MkO1N|Y4OjF:L3G+
A2058  NHPyZpVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NIfqeoo{Py53LUOwNEBvVQ>? NGPiSZE4OiCq NIP0T|lFVVOR NUjMeFA6emWmdXPld{B1cGViTVutNVc4PSCHQ{WwxsBjgSB3LX\vcIQhfG9iYX6gZZZmemGpZTDv[kA1PSCwTR?= NXjWclVZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxOFg3QDRpPkKzNVQ5Pjh2PD;hQi=>
H2009 MUjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M17tSVUxOCCwTR?= MmfkO|IhcA>? NE\XbYZFVVOR M2nsV5Jme3WudIOgbY4hTzFxUz3wbIF{\SCjY3P1cZVt[XSrb36gZ49u[mmwZXSge4l1cCCPSz2xO|c2 M1nPZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MUS4Olg1Lz5{M{G0PFY5PDxxYU6=
Su.86.86 MknGR4VtdCCYaXHibYxqfHliQYPzZZk> MnH6OVAxKG6P NHjTbFQ4OiCq MnT5SG1UVw>? MnzrdoV{fWy2czDpckBIOS:VLYDoZZNmKGGlY4XteYxifGmxbjDjc41jcW6nZDD3bZRpKE2NLUG3O|U> MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzF2OE[4OEc,OjNzNEi2PFQ9N2F-
HRE MYHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M{fES|UxOCCwTR?= M{DzUFczKGh? MYTEUXNQ NFLqT2hz\XO3bITzJIlvKEdzL2OtdIhie2ViYXPjeY12dGG2aX;uJINwdWKrbnXkJJdqfGhiTVutNVc4PQ>? MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzF2OE[4OEc,OjNzNEi2PFQ9N2F-
HMEC NHr1VZhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NXezNodyPTByIH7N NHLGfWY4OiCq NWXuPY01TE2VTx?= MVfy[ZN2dHS|IHnuJGcyN1NvcHjhd4Uh[WOldX31cIF1cW:wIHPvcYJqdmWmIIfpeIghVUtvMUe3OS=> Mn:5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzNEi2PFQoRjJ|MUS4Olg1RC:jPh?=
U2OS  NG[4XZlHfW6ldHnvckBCe3OjeR?= MXyyJOK2VQ>? NIH2d5cxNTJ2IHi= M3rid4lv\HWlZYOgdIhwe3Cqb4L5cIF1cW:wIH;mJGNpczFiYYSgd4VzcW6nIEO0OUBifCCkb4ToJINwdmOnboTyZZRqd26|IHHzJIViemy7IHHzJFIhcCCjZoTldkBi\G2rbnnzeJJifGmxbh?= M1XNN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OUO3NVQ4Lz5{MkmzO|E1PzxxYU6=
U2OS  NHyxZ2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\5NE0yOCEEtV2= MWmyOE81QCCq M4PPN4lvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NEfTWHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkmzO|E1Pyd-MkK5N|cyPDd:L3G+
U937 MXzGeY5kfGmxbjDBd5NigQ>? Mli4NVAxNTVyMDDuUS=> NHrDdGc1KGkEoB?= NFv5[3Nl\WO{ZXHz[ZMhfGinIHP5eIFz[WKrbnWtbY5lfWOnZDDDbIsyKGG3dH;wbI9{eGixconsZZRqd25iYYSgV4VzOjl4wrDhcoQheHKndnXueJMhS2SlMkXBJIRwf26{ZXf1cIF1cW:w NV3pN2k6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4Olk5PjlpPkKyPFY6QDZ7PD;hQi=>
U937 NFXBdZlHfW6ldHnvckBCe3OjeR?= M2\RSFExOCCwTR?= M2K5VVQhcMLi NHTUc3pz\X[ncoPld{B1cGViY4n0ZZJi[mmwZT3pcoR2[2WmIHnubIljcXSrb36gc4bDqDOKLYTofY1q\GmwZTDpcoNwenCxcnH0bY9vKGmwdH:gSG5C M3HiSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OE[5PFY6Lz5{Mki2PVg3QTxxYU6=
U937 NGHwVoJHfW6ldHnvckBCe3OjeR?= NWjLdIZSOTByLUWwNEBvVQ>? NYD2[HBmPCCqwrC= MVXpcoR2[2W|IHnuZ5Jm[XOnZDDwbI9{eGixconsZZRqd25ib3[gTFJCYA>? NYjGPJZ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4Olk5PjlpPkKyPFY6QDZ7PD;hQi=>
HL-60 M2LWc2Fxd3C2b4Ppd{BCe3OjeR?= NI\5Xpg{OC9zMECvN|AxKG6P MUmyOEBp MWrEUXNQ NF\HTGlmdmijbnPld{BkgXSjcnHibY5mNWmwZIXj[YQh[XCxcITvd4l{ M4raV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OE[5PFY6Lz5{Mki2PVg3QTxxYU6=
ML-1 NVHtOYpmSXCxcITvd4l{KEG|c3H5 NWXKPGo{OjVxNUCvNVAxKG6P M{HTe|I1KGh? NH3B[WNFVVOR NYW4RYtn\W6qYX7j[ZMh[3m2YYLhZolv\S2rbnT1Z4VlKGGyb4D0c5Nqew>? NXL0SWRqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4Olk5PjlpPkKyPFY6QDZ7PD;hQi=>
HCT116 NIjVWZhHfW6ldHnvckBCe3OjeR?= M{jyVVEhyrWP NXj1b|hFOjRiaB?= NVPPUYVs[WK{b3fheIV{KG:oIHPlcIwh[3mlbHWgZZJz\XO2wrC= MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjVzMEW2NEc,OjJ3MUC1OlA9N2F-
U2OS NITuemRHfW6ldHnvckBCe3OjeR?= NEX0cFgyKML3TR?= MW[yOEBp NFPlVlBi[nKxZ3H0[ZMhd2ZiY3XscEBkgWOuZTDhdpJme3UEoB?= NEXIPWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkWxNFU3OCd-MkK1NVA2PjB:L3G+
Sf9 NIrFfHJHfW6ldHnvckBie3OjeR?= NILUR2VKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGNFUzJxQ4njcIlvKEFiZYjwdoV{e2WmIHnuJIlve2WldDDT[lkh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDbN|NRZS2DVGCgbY5kd3Kyb4LheIlwdiCrboTvJIJqd3SrbonsZZRm\CCqaYP0c45mKEhzIHHmeIVzKDFiaIKgZpkhdGmzdXnkJJNkcW62aXzsZZRqd25iY3;1cpRqdmduIFnDOVAhRSByLkG2JO69VS5? NVHHZmdxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGwPVQ3ODdpPkKxNFk1PjB5PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-chk1(ser345) / CDC25A ; 

PubMed: 27690219     


Western blots for H1299 and A549 cells treated with MK-8776 for various times and assessed for expression of p-chk1 (ser345) and CDC25A.

Cyclin E / pY15-CDK / γH2AX ; 

PubMed: 26595527     


The indicated cell lines were incubated with 2 μM of each drug for 6 h, then lysed and analyzed by western blotting. The top row reflects cells sensitive to MK-8776. The second row reflects cells that are also sensitive to MK-8776, but which fail to degrade cyclin E. The third row reflects MK-8776-resistant cell lines.

27690219 26595527
In vivo Administered 30 minutes after gemcitabine, 4 mg/kg SCH 900776 is sufficient to induce the γ-H2AX biomarker while 8 mg/kg leads to enhanced tumor pharmacodynamic and regression responses relative to gemcitabine or SCH 900776 alone. Dose escalation of SCH 900776 (16 mg/kg and 32 mg/kg) induces incremental improvements in tumor response. Importantly, doses of SCH 900776 associate with robust biomarker activation and improved tumor response are not associated with enhanced toxicity of gemcitabine on hematological parameters in BALB/c mice. [1]

Protocol

Animal Research:[1]
- Collapse
  • Animal Models: Female nude mice injected subcutaneously with A2780 or MiaPaCa2 cells
  • Dosages: ~50 mg/kg
  • Administration: Administered intraperitoneally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 3 mg/mL (7.97 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% propylene glycol
For best results, use promptly after mixing.
5 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 376.25
Formula

C15H18BrN7

CAS No. 891494-63-6
Storage powder
in solvent
Synonyms N/A
Smiles CN1C=C(C=N1)C2=C3N=C(C(=C(N3N=C2)N)Br)C4CCCNC4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00779584 Completed Drug: MK-8776|Drug: Gemcitabine Hodgkin Disease|Lymphoma Non-Hodgkin|Neoplasms Merck Sharp & Dohme Corp. October 17 2008 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to know whether your product S2735 is the optically pure R enantiomer or whether it is a racemic mix.

  • Answer:

    Our S2735 MK-8776 (SCH 900776) is R enantiomer.

Chk Signaling Pathway Map

Chk Inhibitors with Unique Features

Related Chk Products

Tags: buy MK-8776|MK-8776 ic50|MK-8776 price|MK-8776 cost|MK-8776 solubility dmso|MK-8776 purchase|MK-8776 manufacturer|MK-8776 research buy|MK-8776 order|MK-8776 mouse|MK-8776 chemical structure|MK-8776 mw|MK-8776 molecular weight|MK-8776 datasheet|MK-8776 supplier|MK-8776 in vitro|MK-8776 cell line|MK-8776 concentration|MK-8776 nmr|MK-8776 in vivo|MK-8776 clinical trial|MK-8776 inhibitor|MK-8776 Cell Cycle inhibitor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID